Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016923
Chunk: 69

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 69
---
 of the important factors that could cause actual results to differ materially from our forward- looking statements. Please also see the section entitled “Cautionary Note Regarding Forward-Looking Statements” and “Market, Industry and Other Data.”

This section presents management’s perspective on our financial condition and results of operations. The following discussion and analysis (the “MD&A”) is intended to highlight and supplement data and information presented elsewhere in this prospectus. The MD&A is also intended to provide you with information that will assist you in understanding our consolidated financial statements, the changes in key items in those consolidated financial statements from year to year, and the primary factors that accounted for those changes. To the extent that this discussion describes prior performance, the descriptions relate only to the periods listed, which may not be indicative of our future financial outcomes. In addition to historical information, this discussion contains forward-looking statements that involve risks, uncertainties, and assumptions that could cause the Company’s financial results to differ materially from management’s expectations. Factors that could cause such differences are discussed in the “Cautionary Note Regarding Forward-Looking Statements” section of this prospectus and in the “Risk Factors” in this prospectus.

Our MD&A is organized as follows:

| ● 
 ● | Company                                                                                                                       
 Overview – Discussion of our business plan and strategy to provide context for the remainder of the MD&A.                     
 Results                                                                                                                       
 of Operations – Analysis of our financial results comparing the three months ended March 31, 2025, to the comparable period   
 in 2024 as well as the year ended December 31, 2024, to the year ended December 31, 2023.                                     |
|:--|:------------------------------------------------------------------------------------------------------------------------------|
| ● | Liquidity                                                                                                                     
 and Capital Resources – Analysis of changes in our cash flows and discussion of our financial condition and potential sources 
 of liquidity.                                                                                                                 |
| ● | Critical                                                                                                                      
 Accounting Estimates – Accounting estimates are those estimates made in accordance with U.S. generally accepted accounting    
 principles (“GAAP”) that we believe are important to understanding the assumptions and judgments incorporated in our          
 reported financial results and forecasts.                                                                                     |

Company Overview

Business

We develop noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (“AI”). One of our diagnostic tests analyzes cell populations, including cancer and cancer-related cells, that are indicative of a specific diseased state.

Our diagnostic test,